No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.

Détails

Ressource 1Télécharger: article.pdf (1037.00 [Ko])
Etat: Public
Version: de l'auteur
Licence: CC BY 4.0
ID Serval
serval:BIB_4A53A3D43CC0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
Périodique
BMC research notes
Auteur(s)
Claude F., Rochat I., Hafen G.M.
ISSN
1756-0500 (Electronic)
ISSN-L
1756-0500
Statut éditorial
Publié
Date de publication
03/2019
Volume
12
Numéro
1
Pages
115
Langue
anglais
Résumé
Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period.
Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.
Pubmed
Création de la notice
24/09/2019 14:12
Dernière modification de la notice
01/10/2019 7:08
Données d'usage